“The current problem has uncovered some structural weaknesses while in the EU’s medicines provide chain as well as a large dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides said. She suggested that offer chain difficulties be resolved within an EU pharmaceutical syste